OPKO Health, Inc. (NASDAQ:OPK) Short Interest Down 14.0% in December

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) saw a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 84,800,000 shares, a decline of 14.0% from the November 30th total of 98,570,000 shares. Based on an average trading volume of 3,950,000 shares, the short-interest ratio is currently 21.5 days. Currently, 27.4% of the shares of the stock are sold short.

OPKO Health Stock Down 0.7 %

OPK stock traded down $0.01 during midday trading on Monday, hitting $1.47. The company's stock had a trading volume of 2,755,132 shares, compared to its average volume of 6,676,894. The company's fifty day moving average price is $1.55 and its 200 day moving average price is $1.49. OPKO Health has a twelve month low of $0.85 and a twelve month high of $1.76. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The stock has a market capitalization of $1.00 billion, a P/E ratio of -7.74 and a beta of 1.62.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on OPK shares. HC Wainwright reissued a "buy" rating and issued a $3.00 target price on shares of OPKO Health in a research note on Thursday, September 26th. Piper Sandler reiterated an "overweight" rating and issued a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th. Barrington Research restated an "outperform" rating and set a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th. Finally, StockNews.com downgraded shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Thursday.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost purchased 280,183 shares of the firm's stock in a transaction that occurred on Friday, November 8th. The shares were acquired at an average price of $1.50 per share, for a total transaction of $420,274.50. Following the completion of the acquisition, the chief executive officer now directly owns 211,512,405 shares in the company, valued at approximately $317,268,607.50. The trade was a 0.13 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders purchased 1,304,255 shares of company stock valued at $2,024,605. Insiders own 47.26% of the company's stock.

Hedge Funds Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently made changes to their positions in the company. CIBC Asset Management Inc increased its position in OPKO Health by 79.1% during the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company's stock worth $25,000 after buying an additional 8,978 shares during the last quarter. Hollencrest Capital Management increased its holdings in shares of OPKO Health by 14.0% during the 2nd quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company's stock worth $112,000 after acquiring an additional 11,020 shares during the last quarter. FMR LLC raised its stake in OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 11,089 shares during the period. PFG Investments LLC raised its stake in OPKO Health by 2.5% in the 2nd quarter. PFG Investments LLC now owns 960,965 shares of the biotechnology company's stock valued at $1,201,000 after acquiring an additional 23,700 shares during the period. Finally, Private Advisor Group LLC lifted its holdings in OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 25,000 shares during the last quarter. 64.63% of the stock is owned by institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.